Hearing Aids and Dementia: What the Research Actually Says

People search for information about hearing aids and dementia when they notice memory changes in a family member who also has hearing loss, when a physician mentions the connection, or when they read headlines about hearing loss as a dementia risk factor. The research shows a consistent association: untreated hearing loss is linked to faster cognitive decline and higher dementia rates in observational studies. However, the first large randomized trial to test whether treating hearing loss prevents cognitive decline found no overall benefit. This guide explains what the research actually says, what it does not say, and what to do if you or a family member has hearing loss.

What the research says about hearing loss and dementia

Observational research over the past 15 years has consistently found that adults with untreated hearing loss have higher rates of cognitive decline and dementia than adults with normal hearing. These studies follow large groups of people over time, measuring hearing at baseline and tracking who develops dementia years later. The relationship is dose-dependent: worse hearing loss correlates with higher dementia risk.

Observational evidence: association, not causation

A 2011 study by Lin and colleagues published in Archives of Neurology followed 639 adults for an average of 12 years and found that hearing loss was independently associated with incident dementia. Compared with adults with normal hearing, those with mild hearing loss had nearly twice the risk of developing dementia, those with moderate loss had three times the risk, and those with severe loss had five times the risk (Lin et al., Archives of Neurology, 2011). This study controlled for age, sex, race, education, diabetes, smoking, and hypertension, suggesting that hearing loss contributes to dementia risk independently of those factors.

A 2024 systematic review and meta-analysis (Yu et al., Ageing Research Reviews) pooled data from 50 cohort studies including more than 1.5 million participants. The review found that adults with hearing loss had a 35% higher risk of incident dementia compared with those with normal hearing (hazard ratio 1.35, 95% confidence interval 1.26 to 1.45). For every 10 decibels of worsening hearing, dementia risk increased by 16% (Yu et al., Ageing Research Reviews, 2024).

These observational studies show correlation, not causation. People with hearing loss may differ from people with normal hearing in ways that researchers cannot fully measure or control for, such as vascular health, brain reserve, or unmeasured genetic factors. Observational data cannot prove that treating hearing loss will reduce dementia risk. That question requires a randomized controlled trial.

The ACHIEVE randomized trial: null primary endpoint, subgroup signal

The ACHIEVE study (Aging and Cognitive Health Evaluation in Elders) was the first large randomized controlled trial to test whether hearing intervention reduces cognitive decline in older adults. The trial was funded by the National Institutes of Health and conducted at four sites across the United States. Results were published in The Lancet in July 2023 (trial registration NCT03243422).

Study design and participants

ACHIEVE enrolled 977 adults aged 70 to 84 with untreated hearing loss and no substantial cognitive impairment at baseline. Participants were recruited from two populations:

• ARIC cohort (n=238): Older adults participating in the Atherosclerosis Risk in Communities study, a long-running cardiovascular health study. This cohort was older, had more cardiovascular risk factors, lower baseline cognitive scores, and faster rates of cognitive decline than the volunteer cohort.
• De novo cohort (n=739): Healthy volunteers recruited from the community. This cohort was younger, healthier, and had higher baseline cognitive function.

Participants were randomized 1:1 to hearing intervention (audiologist-fitted hearing aids plus audiological counseling and support) or a health education control group (sessions on healthy aging topics such as chronic disease prevention). Both groups were followed every six months for three years. The primary endpoint was 3-year change in a global cognitive score combining performance on multiple cognitive tests (Lin et al., The Lancet, 2023).

Primary analysis: no significant difference

In the primary analysis combining the ARIC and de novo cohorts, 3-year cognitive decline was not significantly different between the hearing intervention group and the health education control group. The difference between groups was 0.002 standard deviations (95% confidence interval: -0.077 to 0.081, p=0.96). This is a null result: hearing aids did not reduce cognitive decline overall.

The trial was well-designed and well-executed. Participants in the hearing intervention group received high-quality audiological care, wore their hearing aids consistently, and reported substantial improvement in communication ability. The null primary endpoint means that, in this sample of older adults with hearing loss, three years of hearing aid use did not slow cognitive decline on average (Lin et al., The Lancet, 2023).

Prespecified subgroup analysis: 48% reduction in the ARIC cohort

The trial protocol included a prespecified sensitivity analysis stratified by recruitment source (ARIC versus de novo). This analysis found a significant difference in the effect of hearing intervention between the two cohorts (p for interaction = 0.010). In the ARIC cohort (n=238, older adults with higher cardiovascular risk), hearing intervention was associated with a 48% reduction in 3-year cognitive decline compared with the control group (difference 0.191 standard deviations, 95% confidence interval: 0.022 to 0.360, p=0.027). In the de novo cohort (n=739, healthier volunteers), hearing intervention showed no effect on cognitive decline (difference -0.061 standard deviations, 95% confidence interval: -0.151 to 0.028, p=0.18) (Lin et al., The Lancet, 2023).

A 2025 secondary analysis by Arnold and colleagues tested whether participants with multiple risk factors for cognitive decline received greater benefit from hearing intervention. The analysis used a predictive model for cognitive decline developed in the larger ARIC study and applied it to ACHIEVE participants. Among participants in the top quartile of predicted risk for cognitive decline, hearing intervention slowed cognitive decline by 62% compared with the control group (95% confidence interval: 34% to 94%). The benefit was concentrated in those with multiple baseline risk factors (Arnold et al., Alzheimer's & Dementia, 2025).

What the ACHIEVE trial means

The ACHIEVE trial is the highest-quality evidence to date on whether treating hearing loss reduces cognitive decline. The primary endpoint was null. Hearing aids did not reduce cognitive decline in the full trial population, which included both higher-risk and lower-risk older adults. The subgroup findings (48% reduction in the ARIC cohort, 62% reduction in the highest-risk quartile) are hypothesis-generating. They suggest that hearing intervention may benefit older adults at higher risk for cognitive decline, but these are exploratory findings from subgroup analyses, not the trial's primary result.

Current evidence does not support a general recommendation to treat hearing aids as dementia prevention. If you are considering hearing aids, base the decision on whether hearing loss interferes with your daily life, communication, relationships, work, or safety. Do not expect cognitive protection as the primary benefit.

The Lancet Commission on Dementia: hearing loss as a modifiable risk factor

The Lancet Commission on Dementia is a standing commission of international experts who review evidence on dementia prevention, intervention, and care. The commission's 2020 report identified 12 modifiable risk factors that together account for approximately 40% of worldwide dementias, meaning those dementias could theoretically be prevented or delayed by eliminating the risk factors. Hearing loss in midlife was the single largest modifiable risk factor, contributing an estimated 8% of dementia cases (Livingston et al., The Lancet, 2020).

The 2024 update added two new risk factors (untreated vision loss and high LDL cholesterol) for a total of 14 modifiable risk factors. The updated commission reported that the 14 risk factors now account for nearly half of dementias worldwide. The commission's updated meta-analysis of hearing loss and dementia found that hearing loss increased dementia risk (hazard ratio 1.37, 95% confidence interval 1.00 to 1.87), and that studies with more hearing aid use showed lower dementia risk (Livingston et al., The Lancet, 2024).

The commission recommends that policy makers improve access to affordable hearing aids and reduce harmful noise exposure. The report emphasizes that the evidence for treating hearing loss to reduce dementia risk is now stronger than in 2020, and that using hearing aids appears particularly effective in people with hearing loss who have other risk factors for dementia (Livingston et al., The Lancet, 2024).

However, the commission's recommendations are based on observational evidence and the ACHIEVE subgroup findings, not the ACHIEVE primary endpoint. The commission acknowledges that the ACHIEVE trial's primary analysis was null and that further research is needed. Identifying hearing loss as a modifiable risk factor does not mean that treating it with hearing aids has been proven to prevent dementia in randomized trials.

Why hearing loss might affect cognition: proposed mechanisms

Researchers have proposed three main mechanisms to explain why hearing loss might contribute to cognitive decline and dementia. These mechanisms are plausible and supported by neurobiological and psychological research, but whether treating hearing loss interrupts these pathways remains uncertain.

Effortful listening and cognitive load

When hearing is impaired, the auditory signal that reaches the brain is incomplete or distorted. The brain works harder to fill in missing pieces, reconstruct words, and make sense of degraded speech. This process is called effortful listening. According to the National Institute on Aging, effortful listening consumes cognitive resources that would otherwise be available for memory, reasoning, and attention (NIA, What's the connection between hearing and cognitive health?, accessed October 21, 2026).

The cognitive load hypothesis suggests that chronic effortful listening over years or decades leaves fewer resources for encoding new memories, maintaining attention during complex tasks, and supporting higher-level cognitive functions. Research has shown that older adults with hearing loss perform worse on cognitive tests when tested in noisy conditions compared with quiet conditions, suggesting that cognitive resources are diverted to auditory processing when the signal is poor.

Social isolation and reduced cognitive stimulation

People with untreated hearing loss often avoid social situations because conversations are difficult, frustrating, or embarrassing. They may withdraw from group activities, stop attending events, or limit interactions to one-on-one conversations in quiet environments. This social isolation reduces cognitive stimulation, which is protective against dementia.

Social engagement requires complex cognitive work: tracking multiple speakers, processing rapid speech, remembering context, and generating appropriate responses. When people withdraw from social life, they lose this cognitive workout. Research has consistently found that social isolation is a risk factor for dementia, independent of hearing loss. Hearing loss may contribute to dementia partly by causing social isolation (NIA, Take care of your senses: The science behind sensory loss and dementia risk, accessed October 21, 2026).

Auditory deprivation and structural brain changes

Prolonged lack of auditory input is associated with structural changes in the brain regions that process sound and speech. Neuroimaging studies have shown that adults with hearing loss have accelerated atrophy in the temporal lobes and other brain regions involved in auditory processing and speech comprehension. Some research suggests that hearing loss is associated with reduced brain volume in areas important for memory and cognition, though whether hearing loss causes these changes or they share a common cause (such as vascular damage) is unclear.

The auditory deprivation hypothesis suggests that when the auditory cortex receives less input because of hearing loss, it begins to shrink or reorganize, and these structural changes may affect cognitive function. Structural brain changes are harder to reverse than functional changes, which raises the question of whether treating hearing loss late in life can still protect cognition, or whether earlier intervention is necessary.

Shared pathology: vascular damage and neurodegeneration

Another possibility is that hearing loss and dementia do not have a direct causal relationship but share a common underlying cause. Cardiovascular disease, diabetes, and hypertension damage blood vessels throughout the body, including in the inner ear and the brain. People with cardiovascular risk factors may develop both hearing loss (from damage to the blood supply to the cochlea) and dementia (from vascular damage to the brain). In this scenario, hearing loss is a marker of vascular damage rather than a cause of cognitive decline.

The ACHIEVE trial's finding that hearing intervention benefited the ARIC cohort (which had more cardiovascular risk factors) but not the healthier de novo cohort is consistent with the shared pathology hypothesis. It is also consistent with the possibility that treating hearing loss is most beneficial when other dementia risk factors are present.

What to do next if you or a family member has hearing loss

If you or a family member has hearing loss, address it for the right reasons. Hearing loss interferes with communication, relationships, work, and quality of life. Those are sufficient reasons to seek evaluation and treatment. Do not expect hearing aids to prevent dementia based on current evidence. Here is what to do next.

Get a hearing evaluation

If you suspect you have hearing loss, see an audiologist for a comprehensive hearing evaluation. An audiologist will test your hearing thresholds across frequencies, measure speech understanding, and determine whether you have conductive, sensorineural, or mixed hearing loss. The audiogram shows the degree and pattern of hearing loss and helps determine whether hearing aids are appropriate. For how to read an audiogram, see our audiogram guide.

Adults 18 and older with perceived mild to moderate hearing loss can purchase over-the-counter (OTC) hearing aids without a hearing test or prescription. However, an evaluation by an audiologist is still recommended, especially if you have red flags such as sudden hearing loss, hearing loss in only one ear, dizziness, ear pain, drainage, or a history of ear disease. For the difference between OTC and prescription hearing aids, see our OTC vs prescription hearing aids guide.

For signs of hearing loss, see our signs of hearing loss guide. Common signs include difficulty hearing in noise, asking people to repeat themselves, turning up the TV volume, and feeling exhausted after social events because listening requires so much effort.

Consider hearing aids if hearing loss interferes with your life

Hearing aids improve communication, reduce listening effort, and help you stay connected to the people and activities you care about. Those are the primary benefits you should expect. If hearing loss makes it difficult to follow conversations at dinner, participate in meetings at work, hear the television at a comfortable volume, or talk on the phone, those are valid reasons to consider hearing aids.

For guidance on choosing hearing aids, see our how to choose hearing aids guide. For typical pricing, see our hearing aid cost guide. For insurance coverage options, see our Medicare coverage guide, our insurance coverage guide, and our free hearing aids guide for low-income assistance programs.

Address other modifiable dementia risk factors

The 2024 Lancet Commission on Dementia identified 14 modifiable risk factors that together account for nearly half of dementias worldwide. In addition to hearing loss, these include less education in early life, hypertension, obesity, smoking, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, social isolation, untreated vision loss, and high LDL cholesterol (Livingston et al., The Lancet, 2024).

If you are concerned about dementia risk, work with your physician to address modifiable risk factors you can control. Manage hypertension, maintain a healthy weight, stay physically and socially active, avoid smoking, limit alcohol, treat depression, protect your head from injury, and control cardiovascular risk factors such as diabetes and high cholesterol. The evidence for these interventions is stronger than the evidence for hearing aids, and they have broader health benefits.

If you notice cognitive changes, see a doctor

If you or a family member has noticed memory problems, confusion, difficulty with familiar tasks, or other cognitive changes, see a physician for evaluation. Do not assume that cognitive symptoms are caused by hearing loss or that treating hearing loss will reverse cognitive decline. Memory problems need medical evaluation to rule out treatable causes such as medication side effects, vitamin deficiencies, thyroid disease, depression, or sleep disorders.

Some families notice that a loved one with both hearing loss and cognitive decline seems more confused or withdrawn, and they wonder whether hearing aids will help. Hearing aids may improve communication and reduce frustration, but they are not a treatment for dementia. Cognitive decline and dementia need medical diagnosis and management. For the difference between hearing aids and cochlear implants (which are sometimes considered for older adults with severe hearing loss), see our hearing aid vs cochlear implant guide.

Frequently asked questions